Cited by 2,292Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction ResearchCancer, Lipids, and Metabolism

The DOI matches its Crossref record, with a small difference in title or year; 28 of the 28 references it cites were found in a registry or an index.

C-Reactive Protein Levels and Outcomes after Statin Therapy

Open access

Ridker, Paul M, Cannon, Christopher P., Morrow, David, Rifai, Nader, Rose, Lynda M., McCabe, Carolyn H., Pfeffer, Marc A., Braunwald, Eugene·2005·New England Journal of Medicine

DOI 10.1056/nejmoa042378

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Statins lower the levels of low-density lipoprotein (LDL) cholesterol and C-reactive protein (CRP). Whether this latter property affects clinical outcomes is unknown. METHODS: We evaluated relationships between the LDL cholesterol and CRP levels achieved after treatment with 80 mg of atorvastatin or 40 mg of pravastatin per day and the risk of recurrent myocardial infarction or death from coronary causes among 3745 patients with acute coronary syndromes. RESULTS: Patients in whom statin therapy resulted in LDL cholesterol levels of less than 70 mg per deciliter (1.8 mmol per liter) had lower event rates than those with higher levels (2.7 vs. 4.0 events per 100 person-years, P=0.008). However, a virtually identical difference was observed between those who had CRP levels of less than 2 mg per liter after statin therapy and those who had higher levels (2.8 vs. 3.9 events per 100 person-years, P=0.006), an effect present at all levels of LDL cholesterol achieved. For patients with post-treatment LDL cholesterol levels of more than 70 mg per deciliter, the rates of recurrent events were 4.6 per 100 person-years among those with CRP levels of more than 2 mg per liter and 3.2 events per 100 person-years among those with CRP levels of less than 2 mg per liter; the respective rates among those with LDL cholesterol levels of less than 70 mg per deciliter were 3.1 and 2.4 events per 100 person-years (P<0.001). Although atorvastatin was more likely than pravastatin to result in low levels of LDL cholesterol and CRP, meeting these targets was more important in determining the outcomes than was the specific choice of therapy. Patients who had LDL cholesterol levels of less than 70 mg per deciliter and CRP levels of less than 1 mg per liter after statin therapy had the lowest rate of recurrent events (1.9 per 100 person-years). CONCLUSIONS: Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol. Strategies to lower cardiovascular risk with statins should include monitoring CRP as well as cholesterol.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa042378

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Self-citation
Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events
Ridker, P. M., Rifai, N., Rose, L., Buring, J. E., & Cook, N. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021993 · Cited by 3,604
Self-citation
C-Reactive Protein and Other Circulating Markers of Inflammation in the Prediction of Coronary Heart Disease
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina
Liuzzo, G., Biasucci, L. M., Gallimore, J. R., Grillo, R. L., Rebuzzi, A. G., Pepys, M. B., & Maseri, A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199408183310701 · Cited by 2,354
Effect of Statin Therapy on C-Reactive Protein Levels
Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators (2001) · JAMA · doi:10.1001/jama.286.1.64 · Cited by 1,644
Self-citation
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
Self-citation

Flagged first, then by citations

Show all 28 references

Research works printed but not linked: 1

Davignon J, 2004, Circulation, 109, III

Sorted by citations

Items 801–900 of 1,000

Chasing LDL cholesterol to the bottom — PCSK9 in perspective
Libby, P., & Tokgözoğlu, L. S. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-022-00085-x · Cited by 41
Is Taurine A Biomarker?
Schuller‐Levis, G., & Park, E. (2006) · Advances in clinical chemistry · doi:10.1016/s0065-2423(05)41001-x · Cited by 37
Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment
Baldassarre, D., Porta, B., Camera, M., Amato, M., Arquati, M., Brusoni, B., Fiorentini, C., Montorsi, P., Romano, S. M., Veglia, F., et al. (2009) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2008.10.003 · Cited by 38
Managing Older Patients with Coexistent Asthma and Chronic Obstructive Pulmonary Disease
McDonald, V. M., Higgins, I., & Gibson, P. G. (2012) · Drugs & Aging · doi:10.1007/s40266-012-0042-z · Cited by 38
Photodynamic therapy for the treatment of atherosclerotic plaque: Lost in translation?
Jain, M. K., Zellweger, M., Wagnières, G., van den Bergh, H., Cook, S., & Giraud, M. (2016) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12238 · Cited by 37
UNRESOLVED ISSUES IN DIALYSIS: Inflammatory Biomarkers and Cardiovascular Risk: Association or Cause and Effect?
Rao, M., Jaber, B. L., & Balakrishnan, V. S. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00138.x · Cited by 37
The Dynamics of Statins
Amarenco, P., & Moskowitz, M. A. (2006) · Stroke · doi:10.1161/01.str.0000201856.90105.ab · Cited by 39
Effects of Statin Therapy on the Development and Progression of Heart Failure: Mechanisms and Clinical Trials
Khush, K. K., & Waters, D. D. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.05.003 · Cited by 37
Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Klein, L. W. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.039 · Cited by 38
Role of biomarkers in risk stratification of acute coronary syndrome
Nagesh, C. M., & Roy, A. (2010) · The Indian Journal of Medical Research · doi:10.4103/0971-5916.73419 · Cited by 35
Baseline serum C-reactive protein and death from colorectal cancer in the NHANES III cohort
Swede, H., Hajduk, A. M., Sharma, J., Rawal, S., Rasool, H., Vella, A. T., Tobet, R. E., & Stevens, R. G. (2013) · International Journal of Cancer · doi:10.1002/ijc.28504 · Cited by 36
Inflammation in Cardiovascular Tissue Engineering: The Challenge to a Promise: A Minireview
Simionescu, A., Schulte, J. B., Fercana, G., & Simionescu, D. T. (2011) · International Journal of Inflammation · doi:10.4061/2011/958247 · Cited by 36
RETRACTED: Prediction of Cardiovascular Events in Statin-Treated Stable Coronary Patients by Lipid and Nonlipid Biomarkers
Arsenault, B. J., Barter, P. J., DeMicco, D. A., Bao, W., Preston, G. M., LaRosa, J. C., Grundy, S. M., DEEDWANIA, P. C., Greten, H., WENGER, N. K., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.06.052 · Cited by 36
Retracted
Inflammation‐regulatory microRNAs: Valuable targets for intracranial atherosclerosis
Li, J., Li, K., & Chen, X. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24487 · Cited by 36
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial
Qamar, A., Giugliano, R. P., Bohula, E. A., Park, J., Jarolı́m, P., Murphy, S. A., Blazing, M. A., Califf, R. M., Cannon, C. P., D, E. B. M., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.06.038 · Cited by 36
Self-citation
Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imaging
Giovanni, G. D., & Nicholls, S. J. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100366 · Cited by 36
Predictive Value of C-Reactive Protein for Major Postoperative Complications Following Off-Pump Coronary Artery Bypass Surgery Prospective and Observational Trial
Kim, D. H., Shim, J., Hong, S. W., Cho, K. R., Kang, S. Y., & Kwak, Y. L. (2009) · Circulation Journal · doi:10.1253/circj.cj-08-1010 · Cited by 38
Drug Insight: immunomodulatory effects of statins—potential benefits for renal patients?
Steffens, S., & Mach, F. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0217 · Cited by 35
Adipokines--targeting a root cause of cardiometabolic risk
Bakhai, A. (2008) · QJM · doi:10.1093/qjmed/hcn066 · Cited by 37
Antipsychotics and Metabolics in the Post-CATIE Era
Meyer, J. M. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_45 · Cited by 36
The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk
Schuster, H. (2007) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.5.2.177 · Cited by 40
Therapies for diabetic dyslipidaemia
Bell, D. S. H., Badarin, F. J. A., & O’Keefe, J. H. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01342.x · Cited by 36
The Year in Non-ST-Segment Elevation Acute Coronary Syndromes
Giugliano, R. P., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.06.051 · Cited by 36
Implications of Rosiglitazone and Pioglitazone on Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus
Irons, B. K., Greene, R. S., Mazzolini, T. A., Edwards, K. L., & Sleeper, R. B. (2006) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.2.168 · Cited by 36
Statins: Neurobiological underpinnings and mechanisms in mood disorders
Walker, A. J., Kim, Y., Borissiouk, I., Rehder, R., Dodd, S., Morris, G., Nierenberg, A. A., Maes, M., Fernandes, B. S., Dean, O. M., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.07.012 · Cited by 33
Emerging anti-inflammatory drugs for atherosclerosis
Berman, J. P., Farkouh, M. E., & Rosenson, R. S. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2013.801453 · Cited by 35
Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients
Drolz, A., Horvatits, T., Michl, B., Roedl, K., Schellongowski, P., Holzinger, U., Zauner, C., Heinz, G., Madl, C., Trauner, M. A., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.019 · Cited by 35
Perpetual change: autophagy, the endothelium, and response to vascular injury
Sachdev, U., & Lotze, M. T. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru1116-484rr · Cited by 35
Statins: A New Approach to Combat Temozolomide Chemoresistance in Glioblastoma
Shojaei, S., Alizadeh, J., Thliveris, J. A., Koleini, N., Kardami, E., Hatch, G. M., Xu, F. Y., Hombach‐Klonisch, S., Klonisch, T. C., & Ghavami, S. (2018) · Journal of Investigative Medicine · doi:10.1136/jim-2018-000874 · Cited by 35
New Opportunities for Identification and Reduction of Coronary Risk
Muller, J. E., Tawakol, A. A., Kathiresan, S., & Narula, J. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.12.044 · Cited by 34
Effect of atorvastatin on C-reactive protein and benefits for cardiovascular disease in patients with type 2 diabetes: analyses from the Collaborative Atorvastatin Diabetes Trial
on behalf of the CARDS Investigators, Soedamah‐Muthu, S. S., Livingstone, S. J., Charlton-Menys, V., Betteridge, D. J., Hitman, G. A., Neil, H. A. W., Bao, W., DeMicco, D. A., Preston, G. M., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3586-8 · Cited by 36
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
Liao, J. K. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0037-3 · Cited by 35
Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation
Corsetti, J. P., Zaręba, W., Moss, A. J., Rainwater, D. L., & Sparks, C. E. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.09.012 · Cited by 35
Targeting inflammation to slow or delay functional decline: where are we?
Corsonello, A., Garasto, S., Abbatecola, A. M., Rose, G., Passarino, G., Mazzei, B., Pranno, L., Guffanti, E. E., Bustacchini, S., & Lattanzio, F. (2010) · Biogerontology · doi:10.1007/s10522-010-9289-0 · Cited by 35
What the Statin Trials Have Taught Us
Waters, D. D. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.01.066 · Cited by 35
PreImplantation factor prevents atherosclerosis via its immunomodulatory effects without affecting serum lipids
Chen, Y., Rivera, J., Fitzgerald, M., Hausding, C., Ying, Y.-L., Wang, X., Todorova, K. O., Hayrabedyan, S., Barnea, E. R., & Peter, K. (2016) · Thrombosis and Haemostasis · doi:10.1160/th15-08-0640 · Cited by 36
Molecular Regulatory Pathways Link Sepsis With Metabolic Syndrome: Non-coding RNA Elements Underlying the Sepsis/Metabolic Cross-Talk
Meydan, C., Bekenstein, U., & Soreq, H. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00189 · Cited by 34
Colchicine: an affordable anti-inflammatory agent for atherosclerosis
Thompson, P. L., & Nidorf, S. M. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000552 · Cited by 34
Molecular pathways involved in the cardioprotective effects of intravenous statin administration during ischemia
Mendieta, G., Ben‐Aicha, S., Casaní, L., Badimón, L., Sabaté, M., & Vilahur, G. (2019) · Basic Research in Cardiology · doi:10.1007/s00395-019-0760-z · Cited by 34
Increased circulating CC chemokine levels in the metabolic syndrome are reduced by low‐dose atorvastatin treatment: evidence from a randomized controlled trial
Loughrey, B. V., McGinty, A., Young, I. S., McCance, D. R., & Powell, L. A. (2012) · Clinical Endocrinology · doi:10.1111/cen.12113 · Cited by 34
Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia
Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x280446 · Cited by 34
How to use C-reactive protein in acute coronary care
Biasucci, L. M., Köenig, W., Mair, J. M., Mueller, C. E., Plebani, M., Lindahl, B., Rifai, N., Venge, P., Hamm, C. W., Giannitsis, E., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht435 · Cited by 35
Self-citation
Relation Between Soluble Intercellular Adhesion Molecule-1, Statin Therapy, and Long-Term Risk of Clinical Cardiovascular Events in Patients With Previous Acute Coronary Syndrome (from PROVE IT-TIMI 22)
Ray, K. K., Morrow, D. A., Shui, A. M., Rifai, N., & Cannon, C. P. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.04.024 · Cited by 34
Self-citation
Statin therapy for prevention and treatment of acute and chronic cardiovascular disease: update on recent trials and metaanalyses
Briel, M., Nordmann, A. J., & Bucher, H. C. (2005) · Current Opinion in Internal Medicine · doi:10.1097/01.mol.0000191502.39831.ba · Cited by 34
The Inflammatory Hypothesis
Blankenberg, S., & Yusuf, S. (2006) · Circulation · doi:10.1161/circulationaha.106.652081 · Cited by 33
Intensive Lipid Lowering with Atorvastatin in Coronary Disease
Auer, J., Lamm, G., & Eber, B. (2005) · New England Journal of Medicine · doi:10.1056/nejm200507073530117 · Cited by 34
Relation of Statin Use to Gut Microbial Trimethylamine N-Oxide and Cardiovascular Risk
Li, D. Y., Li, X. S., Chaikijurajai, T., Li, L., Wang, Z., Hazen, S. L., & Tang, W. H. W. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.05.010 · Cited by 32
C‐reactive protein lowering with rosuvastatin in the METEOR study
Peters, S. A. E., Palmer, M. K., Grobbee, D. E., Crouse, J. R., O’Leary, D. H., Raichlen, J. S., & Bots, M. L. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02230.x · Cited by 33
Cholesterol, Lipoproteins, High-sensitivity C-reactive Protein, and Other Risk Factors for Atherosclerosis
Rudolf, J. W., & Lewandrowski, K. B. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2013.11.003 · Cited by 34
Higher C‐Reactive Protein Predicts Worse Prognosis in Acute Heart Failure Only in Noninfected Patients
Lourenço, P., Araújo, J. P., Paulo, C., Mascarenhas, J., Friões, F., Azevedo, A., & Bettencourt, P. (2010) · Clinical Cardiology · doi:10.1002/clc.20812 · Cited by 33
Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy
Koskinas, K. C., Zaugg, S., Yamaji, K., García‐García, H. M., Taniwaki, M., Klingenberg, R., Moschovitis, A., Lüscher, T. F., van Tits, L. J., Matter, C. M., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.015 · Cited by 33
Visualization of atherosclerosis as detected by coronary artery calcium and carotid intima-media thickness reveals significant atherosclerosis in a cross-sectional study of psoriasis patients in a tertiary care center
Santilli, S., Kast, D. R., Grozdev, I., Cao, L. Y., Feig, R. L., Golden, J. B., Debanne, S. M., Gilkeson, R., Orringer, C. E., McCormick, T. S., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0947-0 · Cited by 33
High-Sensitivity C-Reactive Protein Is a Predictor of Coronary Microvascular Dysfunction in Patients with Ischemic Heart Disease
Tong, D. C., Whitbourn, R., MacIsaac, A. I., Wilson, A., Burns, A., Palmer, S. C., & Layland, J. J. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00081 · Cited by 33
Functionality of C-Reactive Protein for Atheroprotection
Singh, S. K., & Agrawal, A. C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01655 · Cited by 36
DNA Methylation Patterns from Peripheral Blood Separate Coronary Artery Disease Patients with and Without Heart Failure
Bain, C., Ziemann, M., Kaspi, A., Khan, A. W., Taylor, R., Trahair, H., Khurana, I., Kaipananickal, H., Wallace, S. K. A., El‐Osta, A., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.12810 · Cited by 33
Perioperative CRP: A novel inflammation‐based classification in gastric cancer for recurrence and chemotherapy benefit
Lü, J., Xu, B., Xue, Z., Xie, J., Zheng, C., Huang, C., & Li, P. (2020) · Cancer Medicine · doi:10.1002/cam4.3514 · Cited by 33
Sudden Cardiac Death and the Role of Medical Therapy
Arshad, A., Mandava, A., Kamath, G. S., & Musat, D. L. (2008) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2007.12.003 · Cited by 32
Impact of systemic treatment of psoriasis on inflammatory parameters and markers of comorbidities and cardiovascular risk: results of a prospective longitudinal observational study
Montaudié, H., Albert-Sabonnadière, C., Acquacalda, É., Fontas, É., Danré, A., Roux, C. H., Ortonne, J. ‐., Lacour, J. ‐., Euller‐Ziegler, L., & Passeron, T. (2013) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12255 · Cited by 33
Pharmacokinetic and Pharmacodynamic Characteristics of Single-dose Canakinumab in Patients With Type 2 Diabetes Mellitus
Noè, A., Howard, C. P., Thuren, T. Y., Taylor, A. E., & Skerjanec, A. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.08.004 · Cited by 33
C-reactive protein predicts long-term mortality independently of low-density lipoprotein cholesterol in patients undergoing percutaneous coronary intervention
Razzouk, L., Muntner, P., Bansilal, S., Kini, A. S., Aneja, A., Mozes, J. I., Ivan, O. C., Jakkula, M., Sharma, S., & Farkouh, M. E. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.05.026 · Cited by 34
Models for Describing Relations Among the Various Statin Drugs, Low-Density Lipoprotein Cholesterol Lowering, Pleiotropic Effects, and Cardiovascular Risk††Conflicts of interest: In the past 2 years, Dr. Robinson has received grants from Abbott Laboratories, Abbott Park, Illinois, Astra-Zeneca, Wilmington, Delaware, Bristol-Myers Squibb, Princeton, New Jersey, GlaxoSmithKline, Pittsburgh, Pennsylvania, Hoffman La Roche, Basel, Switzerland, Merck & Company, West Point, Pennsylvania, Pfizer, New York, New York, Procter & Gamble, Cinncinnati, Ohio, Sankyo, Parsippany, New Jersey, Schering-Plough, Kenilworth, New Jersey, and Takeda Pharmaceuticals, Lincolnshire, Illinois and honoraria for education programs from Merck & Company, and has been a consultant and advisory board member for Merck Schering Plough.
Robinson, J. G. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.11.060 · Cited by 33
Hyperlipidemia as an Instigator of Inflammation: Inaugurating New Approaches to Vascular Prevention
Ridker, P. M. (2012) · Journal of the American Heart Association · doi:10.1161/jaha.112.000497 · Cited by 47
Self-citation
C-reactive protein and cardiovascular diseases: a synthesis of studies based on different designs
Liu, C., & Li, C. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad116 · Cited by 37
Impact of statins as immune-modulatory agents on inflammatory markers in adults with chronic diseases: A systematic review and meta-analysis
Sabeel, S., Motaung, B., Nguyen, K. A., Ozturk, M., Mukasa, S. L., Wolmarans, K. H., Blom, D. J., Sliwa, K. S., Nepolo, E., Günther, G., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0323749 · Cited by 41
Statin treatment before percutaneous cononary intervention.
Leoncini, M., Toso, A., Maioli, M., Tropeano, F., & Bellandi, F. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.05.09 · Cited by 32
Statin Therapy May not Effect NLR and MPV Levels in Patients With Hypercholesterolemia
Güngören, F., Beşli, F., Çalışkan, S., Polat, U., Başar, C., & Serdar, O. A. (2015) · Angiology · doi:10.1177/0003319715604098 · Cited by 32
Anti-inflammatory Therapy for Coronary Atherosclerotic Heart Disease: Unanswered Questions Behind Existing Successes
Ma, J., & Chen, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.631398 · Cited by 36
Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention
Ahn, J., Tantry, U. S., Kang, M. G., Park, H. W., Koh, J., Bae, J. S., Cho, S. Y., Kim, K., Jang, J. Y., Park, J. R., et al. (2022) · JACC Asia · doi:10.1016/j.jacasi.2021.11.014 · Cited by 33
Indications for lowering LDL cholesterol in rheumatoid arthritis: an unrecognized problem.
Soubrier, M., Zerkak, D., & Dougados, M. (2006) · PubMed · Cited by 32
Change in High-Sensitivity C-Reactive Protein Levels Following Initiation of Efavirenz-Based Antiretroviral Regimens in HIV-Infected Individuals
Shikuma, C. M., Ribaudo, H. J., Zheng, Y., Gulick, R. M., Meyer, W. A., Tashima, K. T., Bastow, B., & Kuritzkes, D. R. (2010) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2010.0154 · Cited by 32
Predictors of no-reflow after percutaneous coronary intervention for culprit lesion with plaque rupture in infarct-related artery in patients with acute myocardial infarction
Hong, Y. J., Jeong, M. H., Choi, Y. H., Ko, J. S., Lee, M. G., Kang, W. Y., Lee, S. E., Kim, S. H., Park, K. H., Sim, D. S., et al. (2009) · Journal of Cardiology · doi:10.1016/j.jjcc.2009.03.003 · Cited by 32
Correlation of systemic inflammation with local inflammatory activity in non-culprit lesions: Beneficial effect of statins
Toutouzas, K. P., Drakopoulou, M. I., Markou, V., Karabelas, I., Vaina, S., Vavuranakis, M., Tsiamis, E. G., Tsioufis, C. P., Androulakis, A., & Stefanadis, C. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2006.08.026 · Cited by 32
Pro‐atherogenic lung and oral pathogens induce an inflammatory response in human and mouse mast cells
Oksaharju, A., Lappalainen, J., Tuomainen, A. M., Pussinen, P. J., Puolakkainen, M. H., Kovanen, P. T., & Lindstedt, K. A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00285.x · Cited by 32
Circulating Biomarkers and Abdominal Aortic Aneurysm Size
Hellenthal, F. A. M. V. I., Pulinx, B., Welten, R. J. T. J., Teijink, J. A. W., van Dieijen‐Visser, M. P., Wodzig, W. K. W. H., & Schurink, G. W. H. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2011.09.040 · Cited by 32
Association of high-sensitive C-reactive protein with advanced stage β-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
Pfützner, A., Standl, E., Strotmann, H.-J., Schulze, J., Hohberg, C., Lübben, G., Pahler, S., Schöndorf, T., & Forst, T. M. (2006) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2006.108 · Cited by 33
C-reactive protein genotypes associated with circulating C-reactive protein but not with angiographic coronary artery disease: the LURIC study
Grammer, T. B., Marz, W., Renner, W., Böhm, B. O., & Hoffmann, M. M. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn191 · Cited by 30
CARRISMA: a new tool to improve risk stratification and guidance of patients in cardiovascular risk management in primary prevention
Gohlke, H., Winter, M., Karoff, M., & Held, K. (2007) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000244581.30421.69 · Cited by 31
Different Distribution of Pentraxin 3 and C-Reactive Protein in Coronary Atherosclerotic Plaques
Matsuura, Y., Hatakeyama, K., Imamura, T., Tsuruda, T., Shibata, Y., Kodama, T., Kitamura, K., & Asada, Y. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.12526 · Cited by 31
A Comprehensive Review: Unraveling the Role of Inflammation in the Etiology of Heart Failure
Pepine, D., Șerban, A. M., Capraș, R.-D., Cismaru, C. M., & Filip, G. A. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10519-w · Cited by 36
The role of statins in inflammatory vasculitides
Tremoulet, A. H. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1027818 · Cited by 29
Advancing therapy for hypercholesterolemia
Toutouzas, K. P., Drakopoulou, M. I., Skoumas, I., & Stefanadis, C. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003774080 · Cited by 30
Perioperative Statin Therapy for Patients Undergoing Coronary Artery Bypass Grafting
Barakat, A. F., Saad, M. S., Abuzaid, A., Mentias, A. G., Mahmoud, A., & Elgendy, I. Y. (2016) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2015.09.070 · Cited by 31
An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB
Sniderman, A. D., Toth, P. P., Thanassoulis, G., & Furberg, C. D. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.07.008 · Cited by 31
Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure
Grosman‐Rimon, L., Billia, F., Wright, E., Carasso, S., Elbaz‐Greener, G., Kachel, E., Rao, V. A., & Cherney, D. Z. I. (2019) · Heart Failure Reviews · doi:10.1007/s10741-019-09860-8 · Cited by 32
Oxidative Stress-Induced Ferroptosis in Cardiovascular Diseases and Epigenetic Mechanisms
Li, J., Zhou, Y., Wang, H., Lou, J., Lenahan, C., Gao, S., Wang, X., Deng, Y., Chen, H., & Shao, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.685775 · Cited by 31
Splice factor polypyrimidine tract-binding protein 1 (Ptbp1) primes endothelial inflammation in atherogenic disturbed flow conditions
Hensel, J. A., Nicholas, S.-A. E., Kimble, A. L., Nagpal, A., Omar, O. M., Tyburski, J. D., Jellison, E. R., Ménoret, A., Ozawa, M., Rodríguez, A., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2122227119 · Cited by 27
Atherothrombosis in acute coronary syndromes: mechanisms, markers, and mediators of vulnerability.
Wasserman, E. J., & Shipley, N. M. (2006) · PubMed · Cited by 31
Effect of Intensive Atorvastatin Therapy on Prostaglandin E2 Levels and Metalloproteinase-9 Activity in the Plasma of Patients With Non-ST-Elevation Acute Coronary Syndrome††Conflicts of interest: Drs. Egido and Tuñón have participated on advisory boards and have been invited speakers for Pfizer.
Gómez‐Hernández, A., Sánchez-Galán, E., Ortego, M., Martı́n-Ventura, J. L., Blanco‐Colio, L. M., Tarín, N., Jimenez-Nacher, J. J., López‐Bescós, L., Egido, J., & Tuñón, J. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.090 · Cited by 31
Relationship Between Markers of Inflammation and Brachial-Ankle Pulse Wave Velocity in Japanese Men
Andoh, N., Minami, J., Ishimitsu, T., Ohrui, M., & Matsuoka, H. (2006) · International Heart Journal · doi:10.1536/ihj.47.409 · Cited by 31
C‐reactive protein specifically binds to Fcγ receptor type I on a macrophage‐like cell line
Tron, K., Manolov, D., Röcker, C., Kächele, M., Torzewski, J., & Nienhaus, G. U. (2008) · European Journal of Immunology · doi:10.1002/eji.200738002 · Cited by 31
Statin Therapy for the Prevention of Atrial Fibrillation: A Meta‐analysis of Randomized Controlled Trials
Wang, Z., Zhang, Y., Gao, M., Wang, J., Wang, Q., Wang, X., Su, L., & Hou, Y. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.11.1051 · Cited by 31
HMG-CoA Reductase Inhibitors in Chronic Heart Failure
Laufs, U., Custodis, F., & B�hm, M. (2006) · Drugs · doi:10.2165/00003495-200666020-00002 · Cited by 31
Unraveling Pleiotropic Effects Of Statins
Arslan, F., Pasterkamp, G., & de Kleijn, D. P. V. (2008) · Circulation Research · doi:10.1161/circresaha.108.182220 · Cited by 31
Predictors of high sensitivity C-reactive protein levels in patients with systemic lupus erythematosus
Lee, S.-S., Singh, S., Magder, L., & Petri, M. (2008) · Lupus · doi:10.1177/0961203307085878 · Cited by 30
Strategies for vascular disease prevention: The role of lipids and related markers including apolipoproteins, low-density lipoproteins (LDL)-particle size, high sensitivity C-reactive protein (hs-CRP), lipoprotein-associated phospholipase A2 (Lp-PLA2) and lipoprotein(a) (Lp(a))
Dallmeier, D., & Köenig, W. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.01.003 · Cited by 32
Stable Ischemic Heart Disease
Padala, S. K., Sidhu, M. S., & Boden, W. E. (2016) · Springer eBooks · doi:10.1007/978-3-642-37393-0_70-2 · Cited by 30
Urinary 11-dehydro-thromboxane B2 levels are associated with vascular inflammation and prognosis in atherosclerotic cardiovascular disease
Wang, N., Vendrov, K. C., Simmons, B., Schuck, R. N., Stouffer, G. A., & Lee, C. R. (2017) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2017.11.003 · Cited by 30
Clinical impact of high-sensitivity C-reactive protein during follow-up on long-term adverse clinical outcomes in patients with coronary artery disease treated with percutaneous coronary intervention
Shitara, J., Ogita, M., Wada, H., Tsuboi, S., Endo, H., Doi, S., Konishi, H., Naito, R., Dohi, T., Kasai, T., et al. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.06.002 · Cited by 30
Adverse pregnancy outcomes, ‘stillbirths and early neonatal deaths’ in Mutare district, Zimbabwe (2014): a descriptive study
Chaibva, B. V., Olorunju, S. A. S., Nyadundu, S., & Beke, A. K. (2019) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-019-2229-3 · Cited by 30
How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors
Cybulska, B., Kłosiewicz−Latoszek, L., Penson, P. E., Nabavi, S. M., Lavie, C. J., & Banach, M. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.12.008 · Cited by 30

Authors: Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E.
Affiliations: Brigham and Women's Hospital (US)
ORCID: Ridker, Paul M
Cannon, Christopher P.
Morrow, David
Rifai, Nader
Rose, Lynda M.
Pfeffer, Marc A.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-01-06
Volume: 352
Issue: 1
Pages: 20-28
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa042378
OpenAlex: W2118154631
Cited by: 2,292
References: 28
Citations by year: 2026: 32 · 2025: 46 · 2024: 47 · 2023: 52 · 2022: 70 · 2021: 58 · 2020: 74 · 2019: 64 · 2018: 72 · 2017: 54 · 2016: 78 · 2015: 62 · 2014: 67 · 2013: 93 · 2012: 88
FWCI: 282.76
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords: C-reactive protein, statin therapy, LDL cholesterol, atorvastatin, pravastatin, acute coronary syndrome, reinfarction, coronary death, cardiovascular risk, lipid-lowering targets
MeSH terms: Atorvastatin, Gatifloxacin, Anticholesteremic Agents, C-Reactive Protein, Coronary Disease, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Pyrroles, Risk Factors, Biomarkers, Incidence, Proportional Hazards Models, Pravastatin, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Fluoroquinolones, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

C-Reactive Protein Levels and Outcomes after Statin Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks